newsfilter
← Latest News
Business Wire·

Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting

- Long-term follow-up data for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in advanced bladder cancer to be featured as oral presentation – - Updated Phase 1 data on first-in-class